Developing precision medicines for kidney diseases
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
News & HIGHLIGHTs
Visit our news page for the latest press releases
August 12, 2021
Download the latest Chinook Corporate Presentation
The atrasentan phase 3 ALIGN clinical trial is enrolling patients with IgA nephropathy and the atrasentan phase 2 AFFINITY clinical trial is enrolling patients with proteinuric glomerular diseases.
Advancing a pipeline of precision medicines for kidney diseases.
Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.
October 15, 2021
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021